Kathleen Goetz, Director at abrdn Life Sciences Investors (HQL), bought 400 shares at $13.32 ($5K) on 2024-04-09, disclosed to the SEC on 2024-04-12.
Open-market purchase of $5k HQL by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| Filing → |
| THQ | BUY | 2024-04-12 | $12K | — | Filing → |
| HQL | BUY | 2022-03-24 | $2K | — | Filing → |
| HQH | BUY | 2022-03-24 | $2K | — | Filing → |